Key Insights

Highlights

Treatment Research

8 treatments under study, led by Erythropoietin

Related Conditions

Often studied with 7 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Not Yet Recruiting1
Recruiting1

Clinical Trials (2)

Showing 2 of 2 trials
NCT07902830Phase 2Not Yet Recruiting

A Study to Investigate the Safety and Tolerability of Granulocyte-colony Stimulating Factor (G-CSF) Dosage Reduction in Mavorixafor-treated Participants With Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia Disorders

NCT05931718Recruiting

Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia

Showing all 2 trials

Research Network

Common Treatments

  • Erythropoietin1
  • Cytokine Essays1
  • Fecal Microbiome1
  • Luspatercept1
  • Granulocyte Colonystimulating Factor1

Active Sponsors

  • X4 Pharmaceuticals1
  • Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico1

Related Conditions

  • Autoimmune Neutropenia2
  • Autoimmune Hemolytic Anemia1
  • Cold Agglutinin Disease1
  • Acquired Primary Autoimmune And Idiopathic Chronic Neutropenia Disorders1
  • Chronic Neutropenia1

Activity Timeline